Briggs Morrison, M.D., has served as a member of our board of directors since June 2018 and as Chair of our board of directors since February 2026. Dr. Morrison also served as our lead independent director from June 2023 to February 2026. Prior to joining our board of directors, Dr. Morrison was a member of our Scientific Advisory Board from August 2016 to June 2018. Dr. Morrison has served as Chief Executive Officer of Crossbow Therapeutics, Inc., a privately held biotechnology company, since February 2022. Dr. Morrison previously served as President, Head of Research and Development of Syndax Pharmaceuticals Inc., a publicly-traded biopharmaceutical company, or Syndax, from February 2022 to April 2023, and before that served as Chief Executive Officer of Syndax from June 2015 to February 2022. Dr. Morrison has also served as an Entrepreneur Partner at MPM BioImpact (previously MPM Capital) since June 2015. Previously, Dr. Morrison was the Chief Medical Officer and Head of Global Medicines Development at AstraZeneca plc, a biopharmaceutical company, from January 2012 to June 2015. Dr. Morrison currently serves on the boards of directors of the publicly-traded companies CRISPR Therapeutics AG and Werewolf Therapeutics Inc., and previously served on the boards of directors of the publicly-traded companies, Carisma Therapeutics, Inc., Codiak Biosciences, Inc., NextCure, Inc., Oncorus, Inc., Repare Therapeutics Inc., and Syndax. Dr. Morrison holds an M.D. from the University of Connecticut Medical School and a B.S. in biology from Georgetown University. He completed residency training in Internal Medicine at the Massachusetts General Hospital and a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. We believe Dr. Morrison is qualified to serve on our board of directors due to his extensive executive leadership experience, his medical background and training, and his service on the boards of directors of other public and private biopharmaceutical and biotechnology companies.